Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
- 1 November 1998
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 52 (1-3) , 305-319
- https://doi.org/10.1023/a:1006197805041
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.Journal of Clinical Oncology, 1998
- Ovarian ablation in early breast cancer: overview of the randomised trialsThe Lancet, 1996
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor MarkersJNCI Journal of the National Cancer Institute, 1996
- Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.Journal of Clinical Oncology, 1996
- Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators on Node-Negative Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 1993
- Prognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast CancerNew England Journal of Medicine, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988